CNPR Product Knowledge 4

Question 1

A 'contraindication' for a drug means:

Accepted Answer

A clinical situation in which the drug should NOT be used because the risks outweigh the benefits

Answer

A contraindication is a specific situation or condition in which a drug must not be used because the risk of harm clearly outweighs any potential benefit.

Question 2

What does 'mechanism of action' (MOA) describe in pharmaceutical product knowledge?

Accepted Answer

How a drug produces its pharmacological effect at the molecular or cellular level

Answer

The mechanism of action explains how a drug interacts with its target (receptor, enzyme, ion channel, etc.) to produce its therapeutic effect.

Question 3

Which route of drug administration typically provides the fastest onset of action?

Accepted Answer

Intravenous (IV)

Answer

Intravenous administration delivers the drug directly into the bloodstream, bypassing absorption and providing the fastest onset of action.

Question 4

What is the role of the FDA's Adverse Event Reporting System (FAERS) in post-market drug surveillance?

Accepted Answer

It collects voluntary reports of adverse drug events to monitor drug safety after approval

Answer

FAERS is a database that supports the FDA's post-marketing safety surveillance by collecting and analyzing voluntary reports of adverse drug events and medication errors.

Question 5

In clinical research, what distinguishes a 'double-blind' study design?

Accepted Answer

Neither the participants nor the investigators know who is receiving the treatment or placebo

Answer

In a double-blind study, neither the participants nor the researchers know who is in the treatment or control group, minimizing bias in reporting and assessment.

(CNPR) Certified National Pharmaceutical Representative Practice Test

(CNPR) Certified National Pharmaceutical Representative Practice Test

CNPR Product Knowledge 4